Novel Functional Testing For Early Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$447,578.00
Summary
About 7.5% of Australians have diabetes and 62% of them will have signs of damage to their eyes within 6 years of diagnosis. Diabetes is 2 to 3 times more common amongst Aboriginal Australians. A group of researchers at the Australian National University are collaborating to bring a new test for the severity of diabetic eye disease to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them recognize sight-threatening damage and to assist in t ....About 7.5% of Australians have diabetes and 62% of them will have signs of damage to their eyes within 6 years of diagnosis. Diabetes is 2 to 3 times more common amongst Aboriginal Australians. A group of researchers at the Australian National University are collaborating to bring a new test for the severity of diabetic eye disease to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them recognize sight-threatening damage and to assist in treatment.Read moreRead less
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Molecular Characterisation Of Early Precursor Lesions Of A Novel Ñserrated Pathwayî Of Colorectal Cancer Using Gene Expression And Proteomics.
Funder
National Health and Medical Research Council
Funding Amount
$318,338.00
Summary
In Australia, CRC is the second highest cause of all cancer-related deaths. If detected early, CRC has a high success rate of cure, but a percentage of precursor lesions escape detection and show aggressive clinical behaviour to progress to CRC. These are difficult to diagnosis with existing technologies. We aim to understand the biology behind sessile serrated adenoma pathways and hence enhance early detection, diagnosis and treatments strategies.